Eli Lilly and Company (LILY34) — Cash Flow-to-Debt Ratio
Eli Lilly and Company (LILY34) has a Cash Flow-to-Debt Ratio of 0.06x as of March 2026, meaning its operating cash flow of R$5.33 Billion could theoretically repay 0% of its total liabilities (R$85.38 Billion) in one year. See Eli Lilly and Company (LILY34) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Eli Lilly and Company Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Eli Lilly and Company across 12 annual periods. For the full cash flow conversion analysis, see Eli Lilly and Company cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Eli Lilly and Company (2014–2025)
Year-by-year debt coverage analysis for Eli Lilly and Company. Check cash flow quality index of Eli Lilly and Company to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (BRL) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.20x | R$16.81 Billion | R$85.94 Billion | ▲ +43.0% |
| 2024 | 0.14x | R$8.82 Billion | R$64.44 Billion | ▲ +27.3% |
| 2023 | 0.11x | R$5.71 Billion | R$53.14 Billion | ▼ -41.1% |
| 2022 | 0.18x | R$7.08 Billion | R$38.84 Billion | ▼ -0.4% |
| 2021 | 0.18x | R$7.26 Billion | R$39.65 Billion | ▲ +15.5% |
| 2020 | 0.16x | R$6.50 Billion | R$40.99 Billion | ▲ +20.2% |
| 2019 | 0.13x | R$4.84 Billion | R$36.68 Billion | ▼ -18.7% |
| 2018 | 0.16x | R$5.52 Billion | R$34.08 Billion | ▼ -3.6% |
| 2017 | 0.17x | R$5.62 Billion | R$33.39 Billion | ▼ -14.0% |
| 2016 | 0.20x | R$4.85 Billion | R$24.80 Billion | ▲ +38.4% |
| 2015 | 0.14x | R$2.96 Billion | R$20.98 Billion | ▼ -33.7% |
| 2014 | 0.21x | R$4.46 Billion | R$20.92 Billion | — |